Q32 Bio (QTTB) Competitors $3.28 +0.14 (+4.46%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends QTTB vs. CKPT, PBYI, CDTX, IPHA, ADAP, BMEA, FATE, STRO, TCRX, and KYTXShould you be buying Q32 Bio stock or one of its competitors? The main competitors of Q32 Bio include Checkpoint Therapeutics (CKPT), Puma Biotechnology (PBYI), Cidara Therapeutics (CDTX), Innate Pharma (IPHA), Adaptimmune Therapeutics (ADAP), Biomea Fusion (BMEA), Fate Therapeutics (FATE), Sutro Biopharma (STRO), TScan Therapeutics (TCRX), and Kyverna Therapeutics (KYTX). These companies are all part of the "pharmaceutical products" industry. Q32 Bio vs. Checkpoint Therapeutics Puma Biotechnology Cidara Therapeutics Innate Pharma Adaptimmune Therapeutics Biomea Fusion Fate Therapeutics Sutro Biopharma TScan Therapeutics Kyverna Therapeutics Q32 Bio (NASDAQ:QTTB) and Checkpoint Therapeutics (NASDAQ:CKPT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk. Which has better valuation & earnings, QTTB or CKPT? Checkpoint Therapeutics has lower revenue, but higher earnings than Q32 Bio. Checkpoint Therapeutics is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQ32 Bio$1.16M34.44-$112.96M-$14.25-0.23Checkpoint Therapeutics$100K1,552.79-$51.85M-$1.84-1.73 Do insiders and institutionals have more ownership in QTTB or CKPT? 31.3% of Q32 Bio shares are owned by institutional investors. Comparatively, 22.0% of Checkpoint Therapeutics shares are owned by institutional investors. 16.1% of Q32 Bio shares are owned by insiders. Comparatively, 2.1% of Checkpoint Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community believe in QTTB or CKPT? Checkpoint Therapeutics received 168 more outperform votes than Q32 Bio when rated by MarketBeat users. However, 75.00% of users gave Q32 Bio an outperform vote while only 67.42% of users gave Checkpoint Therapeutics an outperform vote. CompanyUnderperformOutperformQ32 BioOutperform Votes1275.00% Underperform Votes425.00% Checkpoint TherapeuticsOutperform Votes18067.42% Underperform Votes8732.58% Does the media favor QTTB or CKPT? In the previous week, Checkpoint Therapeutics had 5 more articles in the media than Q32 Bio. MarketBeat recorded 6 mentions for Checkpoint Therapeutics and 1 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 0.43 beat Checkpoint Therapeutics' score of 0.00 indicating that Q32 Bio is being referred to more favorably in the media. Company Overall Sentiment Q32 Bio Neutral Checkpoint Therapeutics Neutral Do analysts rate QTTB or CKPT? Q32 Bio currently has a consensus target price of $29.86, suggesting a potential upside of 810.28%. Checkpoint Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 277.36%. Given Q32 Bio's higher probable upside, research analysts clearly believe Q32 Bio is more favorable than Checkpoint Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Q32 Bio 0 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50Checkpoint Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, QTTB or CKPT? Q32 Bio has a beta of -0.3, suggesting that its share price is 130% less volatile than the S&P 500. Comparatively, Checkpoint Therapeutics has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. Is QTTB or CKPT more profitable? Checkpoint Therapeutics' return on equity of 0.00% beat Q32 Bio's return on equity.Company Net Margins Return on Equity Return on Assets Q32 BioN/A -146.18% -54.49% Checkpoint Therapeutics N/A N/A -659.07% SummaryQ32 Bio beats Checkpoint Therapeutics on 9 of the 17 factors compared between the two stocks. Get Q32 Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for QTTB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QTTB vs. The Competition Export to ExcelMetricQ32 BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$40.68M$6.37B$5.23B$8.96BDividend YieldN/A2.94%5.13%4.04%P/E Ratio-0.239.4187.2917.29Price / Sales34.44310.261,255.8979.02Price / CashN/A61.4443.8235.97Price / Book0.156.055.324.79Net Income-$112.96M$154.90M$122.78M$225.07M7 Day Performance-1.80%-1.72%-0.19%1.51%1 Month Performance4.79%2.69%3.72%4.68%1 Year PerformanceN/A2.78%27.31%20.92% Q32 Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QTTBQ32 Bio2.6782 of 5 stars$3.28+4.5%$29.86+810.3%N/A$40.68M$1.16M-0.2339Short Interest ↑CKPTCheckpoint Therapeutics3.3442 of 5 stars$3.16flat$12.00+279.7%+71.0%$154.31M$47,000.00-1.7210Short Interest ↑Positive NewsPBYIPuma Biotechnology4.1903 of 5 stars$3.14-5.1%$7.00+122.9%-40.4%$154.14M$243.57M6.54200CDTXCidara Therapeutics4.0797 of 5 stars$21.84-9.0%$32.20+47.4%+52.4%$153.91M$44.65M-0.8690Short Interest ↑Positive NewsIPHAInnate Pharma3.3093 of 5 stars$1.84+4.0%$11.50+525.0%-37.4%$152.36M$24.85M0.00220Analyst ForecastNews CoveragePositive NewsADAPAdaptimmune Therapeutics2.2992 of 5 stars$0.59-5.4%$2.79+375.0%-20.0%$150.15M$175.04M-2.67449Short Interest ↑News CoverageBMEABiomea Fusion2.9302 of 5 stars$4.14+4.0%$39.36+850.8%-72.5%$150.03MN/A-1.0350Analyst ForecastFATEFate Therapeutics4.6481 of 5 stars$1.31-10.9%$6.75+417.2%-71.1%$148.63M$13.45M-0.79550Short Interest ↓Positive NewsSTROSutro Biopharma4.4126 of 5 stars$1.79-3.2%$11.13+521.5%-51.1%$147.60M$160.96M-1.11240Short Interest ↑News CoverageGap UpTCRXTScan Therapeutics2.5696 of 5 stars$2.71-2.2%$11.25+315.1%-58.8%$144.64M$9.36M-2.56100News CoverageKYTXKyverna Therapeutics1.2012 of 5 stars$3.31-4.1%$25.71+676.9%N/A$142.90M$7.03M0.0096Short Interest ↑ Related Companies and Tools Related Companies Checkpoint Therapeutics Competitors Puma Biotechnology Competitors Cidara Therapeutics Competitors Innate Pharma Competitors Adaptimmune Therapeutics Competitors Biomea Fusion Competitors Fate Therapeutics Competitors Sutro Biopharma Competitors TScan Therapeutics Competitors Kyverna Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:QTTB) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Q32 Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Q32 Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
